Strategic Funding PetDx has raised substantial venture funding (notably a $62M Series B) and has ongoing growth since its 2021 launch. This indicates potential for enterprise partnerships, scale-up collaborations, and larger pilot programs with veterinary networks seeking cutting-edge diagnostics.

Clinic Partnerships PetDx has existing collaborations with major channels such as Petco and on-site clinics, suggesting a fertile path for expanding partnerships with veterinary networks and pet-care retail clinics to accelerate OncoK9 adoption and drive multi-clinic deployments.

Product Differentiation OncoK9 is a first-in-class multi-cancer early detection blood test using NGS and proprietary analytics. This unique value proposition can be positioned to veterinary oncology specialists and integrated into standard canine cancer screening workflows as a premium service.

Executive Access With leadership changes including a new CEO appointed in 2023, there may be renewed strategic initiatives and willingness to pursue new partnerships, co-development, or channel arrangements that align with corporate growth objectives.

Market Expansion Given the early-stage revenue and the focus on U.S. clinics, explore opportunities to scale through defensible clinical validation studies, payor discussions, and broader adoption across veterinary systems, specialty hospitals, and national chains to increase OncoK9 uptake.